Mark Wolff

7.6k total citations · 2 hit papers
63 papers, 5.3k citations indexed

About

Mark Wolff is a scholar working on Epidemiology, Infectious Diseases and Microbiology. According to data from OpenAlex, Mark Wolff has authored 63 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Epidemiology, 17 papers in Infectious Diseases and 13 papers in Microbiology. Recurrent topics in Mark Wolff's work include Influenza Virus Research Studies (32 papers), Respiratory viral infections research (25 papers) and Pneumonia and Respiratory Infections (9 papers). Mark Wolff is often cited by papers focused on Influenza Virus Research Studies (32 papers), Respiratory viral infections research (25 papers) and Pneumonia and Respiratory Infections (9 papers). Mark Wolff collaborates with scholars based in United States, Madagascar and Chile. Mark Wolff's co-authors include Robert B. Belshe, John J. Treanor, Kenneth M. Zangwill, Paul M. Mendelman, Thomas Rowe, James D. Campbell, James C. King, David I. Bernstein, William C. Gruber and Ken Zangwill and has published in prestigious journals such as New England Journal of Medicine, JAMA and PEDIATRICS.

In The Last Decade

Mark Wolff

63 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in Children

1998 697 citations Robert B. Belshe, Paul M. Mendelman et al. New England Journal of Medicine profile →
Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine

2006 562 citations John J. Treanor, James D. Campbell et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Mark Wolff

Since Specialization

Citations

This map shows the geographic impact of Mark Wolff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Wolff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Wolff more than expected).

Fields of papers citing papers by Mark Wolff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Wolff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Wolff. The network helps show where Mark Wolff may publish in the future.

Co-authorship network of co-authors of Mark Wolff

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Wolff. A scholar is included among the top collaborators of Mark Wolff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Wolff. Mark Wolff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis 2019 ·Vaccine ·W Keitel, Delia Voronca, Robert L. Atmar, Silke Paust, Heather Hill, Mark Wolff, Abbie R. Bellamy	5
2	Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women 2018 ·Vaccine ·Flor M. Muñoz, Lisa A. Jackson, Geeta K. Swamy, Kathryn M. Edwards, Sharon E. Frey, (unknown), Kevin A. Ault, Patricia Winokur, Carey R. Petrie, Mark Wolff, Shital M. Patel, Wendy A. Keitel	19
3	Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children 2014 ·The Pediatric Infectious Disease Journal ·Karen L. Kotloff, Natasha Halasa, Christopher J Harrison, Janet A. Englund, Emmanuel B. Walter, James C. King, C. Buddy Creech, Sara A. Healy, Rowena J Dolor, (unknown), Kathryn M. Edwards, Diana L. Noah, Heather Hill, Mark Wolff	8
4	Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age 2014 ·Journal of the Pediatric Infectious Diseases Society ·Natasha Halasa, Michael A. Gerber, Andrea A. Berry, Edwin L. Anderson, Patricia Winokur, Harry Keyserling, Allison Ross Eckard, Heather Hill, Mark Wolff, Monica McNeal, Kathryn M. Edwards, David I. Bernstein	23
5	Rapid Plasma Reagin Titer Variation in the 2 Weeks After Syphilis Therapy 2012 ·Sexually Transmitted Diseases ·(unknown), Mark Wolff, Arlene C. Seña, David H. Martin, Frieda Behets, Kathleen Van Damme, Peter A. Leone, Linda M. McNeil, (unknown), Edward W. Hook	23
6	Safety and Immunogenicity of Influenza A H5 Subunit Vaccines: Effect of Vaccine Schedule and Antigenic Variant 2011 ·The Journal of Infectious Diseases ·Robert B. Belshe, Sharon E. Frey, Irene Graham, Mark J. Mulligan, Srilatha Edupuganti, Lisa A. Jackson, Anna Wald, Gregory A. Poland, Robert M. Jacobson, Harry Keyserling, Paul Spearman, Heather Hill, Mark Wolff	50
7	Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine after Priming with an Antigenic Variant 2008 ·The Journal of Infectious Diseases ·(unknown), (unknown), Heather Hill, Mark Wolff, Diana L. Noah, (unknown), Thomas Rowe, John J. Treanor	73
8	Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine breakdown → 2006 ·New England Journal of Medicine ·John J. Treanor, James D. Campbell, Kenneth M. Zangwill, Thomas Rowe, Mark Wolff	562
9	Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults 2002 ·Vaccine ·John J. Treanor, Wendy A. Keitel, Robert B. Belshe, James D. Campbell, Gilbert M. Schiff, Ken Zangwill, Mark Wolff, Alexander Klimov, (unknown), Linda C. Lambert	53
10	Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children 2001 ·The Pediatric Infectious Disease Journal ·James C. King, Patricia Fast, Kenneth M. Zangwill, Geoffrey A. Weinberg, Mark Wolff, Lihan Yan, (unknown), Robert B. Belshe, Andrea Kovacs, Jaime G. Deville, Marie T. Jelonek	67
11	QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans 2001 ·Vaccine ·Thomas G. Evans, M. Juliana McElrath, Thomas J. Matthews, David C. Montefiori, Kent J. Weinhold, Mark Wolff, Michael C. Keefer, Esper G. Kallás, Lawrence Corey, Geoffrey J. Gorse, Robert B. Belshe, Barney S. Graham, Paul Spearman, David H. Schwartz, Mark J. Mulligan, Paul A. Goepfert, Patricia Fast, (unknown), Michael F. Powell, Don Francis	106
12	A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection 2000 ·AIDS Research and Human Retroviruses ·M. Juliana McElrath, Lawrence Corey, David C. Montefiori, Mark Wolff, (unknown), Michael C. Keefer, Robert B. Belshe	45
13	Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination 2000 ·The Pediatric Infectious Disease Journal ·Margaret B. Rennels, Janet A. Englund, David I. Bernstein, Genevieve A. Losonsky, Edwin L. Anderson, Michael E. Pichichero, Flor M. Muñoz, Mark Wolff	30
14	Comparison of the Safety, Vaccine Virus Shedding, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold‐Adapted, Administered to Human Immunodeficiency Virus (HIV)–Infected and Non–HIV‐Infected Adults 2000 ·The Journal of Infectious Diseases ·James C. King, John J. Treanor, Patricia Fast, Mark Wolff, Lihan Yan, (unknown), (unknown), Diane O’Brien, (unknown), W. Edward Highsmith, John S. Lambert, Robert B. Belshe	96
15	A case-control study of risk factors for Haemophilus influenzae type B disease in Navajo children. 1999 ·American Journal of Tropical Medicine and Hygiene ·Mark Wolff, Lawrence H. Moulton, Wendy Newcomer, Raymond Reid, M Santosham	7
16	A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgp120 Elicits Broad and Durable CD8⁺Cytotoxic T Lymphocyte Responses in Seronegative Volunteers 1999 ·The Journal of Infectious Diseases ·Thomas G. Evans, Michael C. Keefer, Kent J. Weinhold, Mark Wolff, David C. Montefiori, Geoffrey J. Gorse, Barney S. Graham, M. Juliana McElrath, Mary Lou Clements‐Mann, Mark J. Mulligan, Patricia Fast, Mary Clare Walker, Jean‐Louis Excler, (unknown), James Tartaglia, (unknown)	134
17	The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in Children breakdown → 1998 ·New England Journal of Medicine ·Robert B. Belshe, Paul M. Mendelman, John J. Treanor, James C. King, William C. Gruber, Pedro A. Piedra, David I. Bernstein, Frederick G. Hayden, Karen Kotloff, Ken Zangwill, Dominick Iacuzio, Mark Wolff	697
18	Case-Cohort Analysis of Case-Coverage Studies of Vaccine Effectiveness 1995 ·American Journal of Epidemiology ·Lawrence H. Moulton, Mark Wolff, George Brenneman, Mathuram Santosham	12
19	CHOLECYSTITE AIGUE ALITHIASIQUE A SALMONELLA ENTERITIDIS AU COURS DU SIDA 1993 ·La Presse Médicale ·Martial Thyrault, Bertrand Gachot, Mark Wolff	2
20	Evaluation of Bacterial Polysaccharide Immune Globulin for the Treatment or Prevention of Haemophilus influenzae Type b and Pneumococcal Disease 1992 ·The Journal of Infectious Diseases ·George R. Siber, Claudette M. Thompson, Gregor Reid, (unknown), (unknown), Mark Wolff, Mathuram Santosham	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact